AbCellera Will Present ABCL635 Data in San Diego
The clinical trial results for the investigational menopause treatment will be shared at an October conference.
Updated on Oct. 8, 2026 in Women’s Health
Live Poll
Do you trust that medical research is adequately prioritizing effective treatments for menopause symptoms?
AbCellera is set to present Phase 1/2 clinical trial data for its investigational drug ABCL635 at The Menopause Society 2026 Annual Meeting in San Diego. The presentation scheduled for October 22, 2026, will outline safety and efficacy outcomes for the treatment.
Why it matters
The study aims to address vasomotor symptoms in menopausal women by targeting NK3R on the hypothalamus to help regulate body temperature. ABCL635 is currently being evaluated as a potential best-in-class investigational antibody therapy.
A Phase 2 multicenter, randomized, double-blind, placebo-controlled study provides the efficacy evidence. Up to 80% of women experience vasomotor symptoms, with 12 million in the US suffering from moderate-to-severe cases.
The players
AbCellera
This biotechnology company headquartered in Vancouver specializes in antibody discovery and development.
The Menopause Society
This is a professional organization dedicated to promoting the health and quality of life of women during the menopause transition.
The details
The upcoming presentation at the Hilton Bayfront will include safety findings from a Phase 1 multiple ascending dose study and patient-reported outcomes from the Phase 2 trial. The investigational drug, an NK3R monoclonal antibody antagonist, represents a targeted approach to managing menopausal health.
Timeline
The Menopause Society 2026 Annual Meeting will take place from October 20 to 24, 2026.
The clinical data for ABCL635 will be presented on October 22, 2026, at 6:15 p.m. PDT.
The Big Picture
This presentation expands the clinical evidence for the NK3R antagonist class of drugs as a standard treatment for menopausal vasomotor symptoms. The ABCL635 trial results extend the growing field of NK3R-targeted research by offering a new antibody-based therapeutic option.
This research could eventually offer a new therapeutic alternative for women experiencing moderate-to-severe menopausal symptoms. Patients should monitor future trial outcomes for information regarding potential side effects and eventual clinical availability.
The takeaway
Advancements in targeted therapies like ABCL635 provide researchers and patients with more precise ways to manage common menopausal symptoms. Women experiencing persistent vasomotor symptoms should continue to consult with their physicians about currently approved treatments and emerging clinical trials.
Further reading
Learn more about evolving standards of care in Women’s Health.
More information
Access the AbCellera clinical pipeline details to review the company's current research focus.
Live Poll
Do you trust that medical research is adequately prioritizing effective treatments for menopause symptoms?
